BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in preventing COVID-19 1 . Here we extend a previous phase-I/II trial report 2 by presenting data on the i...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) Vol. 595; no. 7868; pp. 572 - 577
Main Authors: Sahin, Ugur, Muik, Alexander, Vogler, Isabel, Derhovanessian, Evelyna, Kranz, Lena M., Vormehr, Mathias, Quandt, Jasmin, Bidmon, Nicole, Ulges, Alexander, Baum, Alina, Pascal, Kristen E., Maurus, Daniel, Brachtendorf, Sebastian, Lörks, Verena, Sikorski, Julian, Koch, Peter, Hilker, Rolf, Becker, Dirk, Eller, Ann-Kathrin, Grützner, Jan, Tonigold, Manuel, Boesler, Carsten, Rosenbaum, Corinna, Heesen, Ludwig, Kühnle, Marie-Cristine, Poran, Asaf, Dong, Jesse Z., Luxemburger, Ulrich, Kemmer-Brück, Alexandra, Langer, David, Bexon, Martin, Bolte, Stefanie, Palanche, Tania, Schultz, Armin, Baumann, Sybille, Mahiny, Azita J., Boros, Gábor, Reinholz, Jonas, Szabó, Gábor T., Karikó, Katalin, Shi, Pei-Yong, Fontes-Garfias, Camila, Perez, John L., Cutler, Mark, Cooper, David, Kyratsous, Christos A., Dormitzer, Philip R., Jansen, Kathrin U., Türeci, Özlem
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 22.07.2021
Nature Publishing Group
Subjects:
ISSN:0028-0836, 1476-4687, 1476-4687
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first